fullerene c60 has been researched along with alpha-synuclein in 2 studies
| Studies (fullerene c60) | Trials (fullerene c60) | Recent Studies (post-2010) (fullerene c60) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 3,806 | 5 | 2,170 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Davis, TP; Ding, F; Faridi, A; Kakinen, A; Ke, PC; Sun, Y; Yang, Y; Zhang, C | 1 |
| Bolshakova, O; Golomidov, I; Komissarov, A; Latypova, E; Sarantseva, S; Sharoyko, V; Slepneva, Е; Slobodina, A; Tennikova, T; Zherebyateva, O | 1 |
2 other study(ies) available for fullerene c60 and alpha-synuclein
| Article | Year |
|---|---|
Amphiphilic surface chemistry of fullerenols is necessary for inhibiting the amyloid aggregation of alpha-synuclein NACore.
Topics: alpha-Synuclein; Amyloid; Cell Line, Tumor; Fullerenes; Humans; Hydrophobic and Hydrophilic Interactions; Protein Aggregates | 2019 |
The neuroprotective effect of fullerenols on a model of Parkinson's disease in Drosophila melanogaster.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Fullerenes; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2020 |